Antifouling heparin coatings
First Claim
1. A medical device comprising a substrate and a polymeric coating which comprises a biocompatible polymer and heparin,wherein heparin is attached to the biocompatible polymer via a spacer having a grouping that renders a binding site of the heparin molecule accessible by a binding protein,wherein the spacer is of a formula of Y-R-X where X and Y represent two functional groups and R represents a monomeric di-radical;
- wherein X and Y groups are independently selected from the group consisting of hydroxyl, epoxide, carboxyl, amino, imide, aziridine, thiol, phosphoryl, aldehyde, anhydride, acyl halide, silyl, isocyanate, di-isocyanate, carbodiimide, a dihydrazide, a multiaziridine, a multifunctional carbodiimide, a diamine, N-hydroxy-succinamide, acryloxy terminated polyethylene, glycol, methacryloxy terminated polyethylene glycol, and isothiocyanate; and
R is a dextrose di-radical; and
wherein heparin is molecular heparin, a fragment of heparin, or a derivative thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
A medical device comprising a coating thereon comprising a biocompatible polymer and heparin is provided herein. Heparin is coupled with the biocompatible polymer via a spacer having a grouping that renders a binding site of the heparin molecule accessible by a binding protein. The medical device can be implanted in a human being for the treatment of a disease such as atherosclerosis, thrombosis, restenosis, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, or combinations thereof.
396 Citations
23 Claims
-
1. A medical device comprising a substrate and a polymeric coating which comprises a biocompatible polymer and heparin,
wherein heparin is attached to the biocompatible polymer via a spacer having a grouping that renders a binding site of the heparin molecule accessible by a binding protein, wherein the spacer is of a formula of Y-R-X where X and Y represent two functional groups and R represents a monomeric di-radical; -
wherein X and Y groups are independently selected from the group consisting of hydroxyl, epoxide, carboxyl, amino, imide, aziridine, thiol, phosphoryl, aldehyde, anhydride, acyl halide, silyl, isocyanate, di-isocyanate, carbodiimide, a dihydrazide, a multiaziridine, a multifunctional carbodiimide, a diamine, N-hydroxy-succinamide, acryloxy terminated polyethylene, glycol, methacryloxy terminated polyethylene glycol, and isothiocyanate; and R is a dextrose di-radical; and wherein heparin is molecular heparin, a fragment of heparin, or a derivative thereof. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A polymeric composition comprising a biocompatible polymer and heparin,
wherein heparin is attached to the biocompatible polymer via a spacer having a grouping that renders a binding site of the heparin molecule accessible by a binding protein, wherein the spacer has a formula of Y— - R—
X where X and Y represent two functional groups and R represents a monomeric di-radical;wherein X and Y groups are independently selected from the group consisting of hydroxyl, epoxide, carboxyl, amino, imide, aziridine, thiol, phosphoryl, aldehyde, anhydride, acyl halide, silyl, isooyanate, di-isocyanate, carbodiimide, a dihydrazide, a multiaziridine, a multifunctional carbodiimide, a diamine, a primary amine side group on a polymer, N-hydroxy- succinamide, acryloxy terminated polyethylene glycol, methacryioxy terminated polyethylene glycol, and isothiocyanate; and R is a dextrose di-radical; and wherein heparin is molecular heparin, a fragment of heparin, or a derivative thereof. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
- R—
-
21. A method of making a polymeric composition comprising a biocompatible polymer and heparin, comprising:
-
providing a biocompatible polymer which is optionally functionalized, providing heparin which is optionally functionalized, and coupling heparin to the biocompatibie polymer via a spacer having a grouping that renders a binding site of the heparin molecule accessible by a binding protein, wherein the spacer is of a formula of Y—
R—
X where X and Y represent two functional groups and R represents a monomeric di-radical;wherein X and Y groups are independently selected from the group consisting of hydroxyl, epoxide, carboxyl, amino, imide, aziridine, thiol, phosphoryl, aldehyde, anhydride, acyl halide, silyl, isocyanate, di-isocyanate, carbodiimide, a dihydrazide, a multiaziridine, a multifunctional carbodiimide, a diamine, N-hydroxy-succinamide, acryloxy terminated polyethylene glycol, methacryloxy terminated polyethylene glycol, and isothiocyanate; and R is a dextrose di-radical; and wherein heparin is molecular heparin, a fragment of heparin, or a derivative thereof. - View Dependent Claims (22, 23)
-
Specification